Skip to main content
Navigate Up
Sign In
 

91 percent response rate for venetoclax against newly diagnosed AML in older adults


“To date, treatment options for older patients with AML have been limited. We see this new regimen as a paradigm shift in the way we will treat this disease in this population, moving forward,” says Daniel A. Pollyea, investigator at CU Cancer Center and clinical director of Leukemia Services at the CU School of Medicine. 
 
The trial is closely related to the preclinical work of Craig Jordan, investigator at University of Colorado Cancer Center, division chief of the Division of Hematology and the Nancy Carroll Allen Professor of Hematology at the CU School of Medicine.